A Phase 1, Open-Label, First-in-Human, Dose Escalation Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of MT-303 in Adults With Advanced or Metastatic GPC3-Expressing Cancers, Including Hepatocellular Carcinoma
Latest Information Update: 04 Jun 2025
At a glance
- Drugs MT 303 Myeloid Therapeutics (Primary)
- Indications Liver cancer
- Focus Adverse reactions; First in man
- Sponsors Myeloid Therapeutics
Most Recent Events
- 30 May 2025 According to a Myeloid Therapeutics media release, design from this study will be presented at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago taking place from May 30 -June 3, 2025.
- 31 Jul 2024 According to a Myeloid Therapeutics media release, the company has dosed the first patient with MT-303 in a Phase 1 study for hepatocellular carcinoma (HCC).
- 03 Jul 2024 New trial record